| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 86,963 | 100,687 | ||
| Prepaid expenses and other current assets | 3,171 | 2,921 | ||
| Total current assets | 90,134 | 103,608 | ||
| Total fixed assets | 4,790 | - | ||
| Less accumulated depreciation | 3,427 | - | ||
| Fixed assets, net | 1,363 | 1,658 | ||
| Lease right of use assets | 1,750 | 391 | ||
| Restricted cash | 266 | 266 | ||
| Other assets | 85 | 45 | ||
| Total assets | 93,598 | 105,968 | ||
| Accounts payable | 1,118 | 1,953 | ||
| Accrued expenses | 5,149 | 4,318 | ||
| Current portion of term loan payable to a bank | 4,225 | 6,704 | ||
| Current portion of lease liability | 437 | 594 | ||
| Warrant liability | 0 | 1,146 | ||
| Total current liabilities | 10,929 | 14,715 | ||
| Term loan payable to a bank | 0 | 0 | ||
| Other long-term debt | 973 | 939 | ||
| Lease liability, net of current portion | 1,572 | 104 | ||
| Total liabilities | 13,474 | 15,758 | ||
| Common stock, 0.01 par value 150,000,000 shares authorized at september 30, 2025 and december 31, 2024 55,018,457 and 46,933,088 shares issued at september 30, 2025 and december 31, 2024, respectively 54,895,849 and 46,810,480 shares outstanding at september 30, 2025 and december 31, 2024, respectively | 550 | 549 | ||
| Treasury stock (at cost) | 448 | 448 | ||
| Additional paid-in capital | 280,913 | 279,731 | ||
| Accumulated deficit | -200,891 | -189,622 | ||
| Total stockholders' equity | 80,124 | 90,210 | ||
| Total liabilities and stockholders' equity | 93,598 | 105,968 | ||
Candel Therapeutics, Inc. (CADL)
Candel Therapeutics, Inc. (CADL)